FELIPE CORONADO: Open Payments
NPI 1508920059 · DIAMOND BAR, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$899 in 45 payments from 17 companies in 2025. Trend: 2023 $1,224 · 2024 $682 · 2025 $899
Food & beverage: $899
| Company | Payments | Amount |
|---|---|---|
| Incyte Corporation | 11 | $139 |
| ABBVIE INC. | 5 | $111 |
| Novartis Pharmaceuticals Corporation | 4 | $99 |
| Amgen Inc. | 4 | $95 |
| UCB, Inc. | 2 | $79 |
| Arcutis Biotherapeutics, Inc. | 3 | $60 |
| Regeneron Healthcare Solutions, Inc. | 2 | $58 |
| Janssen Biotech, Inc. | 3 | $49 |
| Organon LLC | 2 | $43 |
| LEO Pharma Inc. | 2 | $32 |
Products named: OPZELURA, OTEZLA, COSENTYX, Bimzelx, DUPIXENT, SKYRIZI, Zoryve, RINVOQ.
Industry payments across CA — which companies pay providers there.
